TP53 and B-cell chronic lymphocytic leukemia: SpiD3 also exhibited antiproliferative effects in chemotherapy resistant, TP53 mutant MEC1 and MEC2 CLL cell lines (ref. 30; IC50 = 0.5 μmol/L; Fig. 1C).